Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-991: Pembrolizumab Plus Enzalutamide Plus ADT in mHSPC
2023-507024-24-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Pembrolizumab + enzalutamide + ADT with Placebo + enzalutamide + ADT (2 arms). Primary endpoints: Radiographic progression-free survival (rPFS) and Overall survival (OS). Started Jan 2024; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-507024-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507024-24-00.